Kimberly McGregor

977 total citations
49 papers, 326 citations indexed

About

Kimberly McGregor is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kimberly McGregor has authored 49 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 25 papers in Cancer Research. Recurrent topics in Kimberly McGregor's work include Cancer Genomics and Diagnostics (24 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Kimberly McGregor is often cited by papers focused on Cancer Genomics and Diagnostics (24 papers), Lung Cancer Treatments and Mutations (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Kimberly McGregor collaborates with scholars based in United States, Italy and United Kingdom. Kimberly McGregor's co-authors include Natalie Danziger, Jeffrey S. Ross, Kenneth M. Boucher, John R. Weis, Ethan Sokol, Ignacio Garrido‐Laguna, Geoffrey R. Oxnard, Mark Wade, Hanna Tukachinsky and Ole Gjoerup and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kimberly McGregor

43 papers receiving 320 citations

Peers

Kimberly McGregor
Ezequiel J. Tolosa United States
Clarence Eng United States
Daniela Bianconi Austria
Olga Oikonomidou United Kingdom
Kazuaki Yokomizo Japan
Svenja Wagener‐Ryczek Germany
Pankaj Pande India
Zubaida Fida Hussain Pakistan
Josep Maria de Anta Spain
Nishi Kothari United States
Ezequiel J. Tolosa United States
Kimberly McGregor
Citations per year, relative to Kimberly McGregor Kimberly McGregor (= 1×) peers Ezequiel J. Tolosa

Countries citing papers authored by Kimberly McGregor

Since Specialization
Citations

This map shows the geographic impact of Kimberly McGregor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly McGregor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly McGregor more than expected).

Fields of papers citing papers by Kimberly McGregor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly McGregor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly McGregor. The network helps show where Kimberly McGregor may publish in the future.

Co-authorship network of co-authors of Kimberly McGregor

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly McGregor. A scholar is included among the top collaborators of Kimberly McGregor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly McGregor. Kimberly McGregor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Giannoudis, Athina, Ethan Sokol, Evangelia Razis, et al.. (2024). Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors. npj Precision Oncology. 8(1). 282–282. 4 indexed citations
2.
Gandara, David R., Janakiraman Subramanian, Edgardo S. Santos, et al.. (2024). Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 25(6). e252–e261.e4.
3.
Clark, Allison, Mehrad Tavallai, Dexter X. Jin, et al.. (2024). Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes. Breast Cancer Research. 26(1). 118–118. 2 indexed citations
4.
Zhang, Liangliang, Ryon P. Graf, Hanna Tukachinsky, et al.. (2023). The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer. Clinical Genitourinary Cancer. 22(1). e163–e169.e1. 3 indexed citations
5.
Giannoudis, Athina, Ethan Sokol, Shakti Ramkissoon, et al.. (2023). Abstract P5-14-10: Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. Cancer Research. 83(5_Supplement). P5–14. 1 indexed citations
6.
Tung, Nadine, Hanna Tukachinsky, Erica Gornstein, et al.. (2023). Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing. npj Precision Oncology. 7(1). 76–76. 15 indexed citations
7.
Christopoulos, Petros, Igor Puzanov, Jair Bar, et al.. (2023). A decision-making tool for first-line treatment in advanced non–small-cell lung cancer based on plasma proteome biomarkers.. Journal of Clinical Oncology. 41(16_suppl). 9122–9122. 1 indexed citations
8.
Sivakumar, Smruthy, Dexter X. Jin, Hanna Tukachinsky, et al.. (2022). Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. Nature Communications. 13(1). 7495–7495. 26 indexed citations
9.
Cannon, Timothy Lewis, Ethan S. Sokol, Raymond Wadlow, et al.. (2022). Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cancer Treatment and Research Communications. 32. 100569–100569. 4 indexed citations
10.
Seitz, Robert S., Michael E. Hurwitz, Daniel Bailey, et al.. (2022). Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients. Journal of Translational Medicine. 20(1). 370–370. 7 indexed citations
11.
12.
Grossman, Kenneth, Wallace Akerley, Kenneth M. Boucher, et al.. (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer. 21(1). 510–510. 38 indexed citations
13.
Ross, Jeffrey S., Alexa B. Schrock, Russell W. Madison, et al.. (2021). In search of novel synthetic lethality anti-cancer drug targets in intrahepatic cholangiocarcinoma: MTAP genomic loss.. Journal of Clinical Oncology. 39(3_suppl). 337–337. 1 indexed citations
14.
Madison, Russell W., et al.. (2020). Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors. SHILAP Revista de lepidopterología.
15.
Danziger, Natalie, J. Keith Killian, Eric Williams, et al.. (2020). 957P Ameloblastoma of the head and neck (HNAMB): A comprehensive profiling (CGP) study. Annals of Oncology. 31. S677–S678.
16.
Schrock, Alexa B., Russell W. Madison, Mark R. Rosenzweig, et al.. (2020). <p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <em>ALK</em> Gene Have Durable Responses to ALK Kinase Inhibitors</p>. PubMed. Volume 11. 33–39. 1 indexed citations
17.
Sivapiragasam, Abirami, Prashanth Ashok Kumar, Ethan Sokol, et al.. (2020). Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine. 10(1). 53–61. 36 indexed citations
18.
Gilcrease, Glynn Weldon, David D. Stenehjem, Mark Wade, et al.. (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs. 37(3). 482–489. 17 indexed citations
19.
Vacirca, Jeffrey, Arlene Chan, Zsuzsanna Pápai, et al.. (2018). An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer. Cancer Medicine. 7(5). 1660–1669. 10 indexed citations
20.
Garrido‐Laguna, Ignacio, Kimberly McGregor, Mark Wade, et al.. (2013). A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Investigational New Drugs. 31(5). 1257–1264. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ezequiel J. Tolosa Breakdown of academic impact, for papers by Clarence Eng Breakdown of academic impact, for papers by Daniela Bianconi Breakdown of academic impact, for papers by Olga Oikonomidou Breakdown of academic impact, for papers by Kazuaki Yokomizo Breakdown of academic impact, for papers by Svenja Wagener‐Ryczek Breakdown of academic impact, for papers by Pankaj Pande Breakdown of academic impact, for papers by Zubaida Fida Hussain Breakdown of academic impact, for papers by Josep Maria de Anta Breakdown of academic impact, for papers by Nishi Kothari
Rankless by CCL
2026